Mesa Laboratories Balance Sheet Health
Financial Health criteria checks 1/6
Mesa Laboratories has a total shareholder equity of $403.0M and total debt of $233.0M, which brings its debt-to-equity ratio to 57.8%. Its total assets and total liabilities are $741.8M and $338.8M respectively. Mesa Laboratories's EBIT is $1.4M making its interest coverage ratio 0.3. It has cash and short-term investments of $30.4M.
Key information
57.8%
Debt to equity ratio
US$232.97m
Debt
| Interest coverage ratio | 0.3x |
| Cash | US$30.37m |
| Equity | US$402.96m |
| Total liabilities | US$338.81m |
| Total assets | US$741.77m |
Recent financial health updates
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15
Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt
Dec 08Recent updates
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?
Dec 05Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Aug 09We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking
May 31A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Apr 12Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Dec 20Mesa Laboratories declares $0.16 dividend
Oct 03Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Sep 09Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?
Sep 06Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M
Aug 04Mesa Laboratories declares $0.16 dividend
Jul 07A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
May 06Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%
Apr 09We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt
Dec 08Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($118.4M) exceed its short term liabilities ($44.2M).
Long Term Liabilities: MLAB's short term assets ($118.4M) do not cover its long term liabilities ($294.6M).
Debt to Equity History and Analysis
Debt Level: MLAB's net debt to equity ratio (50.3%) is considered high.
Reducing Debt: MLAB's debt to equity ratio has increased from 27.2% to 57.8% over the past 5 years.
Debt Coverage: MLAB's debt is not well covered by operating cash flow (18.8%).
Interest Coverage: MLAB's interest payments on its debt are not well covered by EBIT (0.3x coverage).